E J Aspinall1, A Weir2, R Sacks-Davis3, T Spelman3, J Grebely4, P Higgs5, S J Hutchinson2, M E Hellard3. 1. Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Glasgow, UK. Electronic address: Esther.Aspinall@nhs.net. 2. Glasgow Caledonian University, Glasgow, UK; Health Protection Scotland, Glasgow, UK. 3. Burnet Institute, Melbourne, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia. 4. The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia. 5. Burnet Institute, Melbourne, Australia; The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia.
Abstract
BACKGROUND: People who inject drugs (PWID) are at risk of hepatitis C virus (HCV). It is plausible that PWID who receive a diagnosis of HCV will reduce their injecting risk out of concern for their injecting partners, although evidence for this is currently limited. The aim of this study was to investigate whether informing PWID of their HCV diagnosis was associated with a change in injecting behaviour. METHODS: Prospective, longitudinal study of PWID recruited from street drug markets across Melbourne, Australia. Interviews and HCV testing were conducted at 3-monthly intervals. The association between receiving a diagnosis of HCV and (i) injecting frequency and (ii) injecting equipment borrowing, was examined using generalized estimating equations (GEE) analysis. RESULTS: Thirty-five individuals received a diagnosis of HCV during the study period. Receiving a diagnosis of HCV was associated with a decrease of 0.35 injections per month (p=0.046) but there was no change in injecting equipment borrowing (p=0.750). CONCLUSIONS: A small reduction in injecting frequency was observed in PWID who received a diagnosis of HCV. This finding should be investigated further in larger studies examining a wider range of injecting risk behaviours.
BACKGROUND:People who inject drugs (PWID) are at risk of hepatitis C virus (HCV). It is plausible that PWID who receive a diagnosis of HCV will reduce their injecting risk out of concern for their injecting partners, although evidence for this is currently limited. The aim of this study was to investigate whether informing PWID of their HCV diagnosis was associated with a change in injecting behaviour. METHODS: Prospective, longitudinal study of PWID recruited from street drug markets across Melbourne, Australia. Interviews and HCV testing were conducted at 3-monthly intervals. The association between receiving a diagnosis of HCV and (i) injecting frequency and (ii) injecting equipment borrowing, was examined using generalized estimating equations (GEE) analysis. RESULTS: Thirty-five individuals received a diagnosis of HCV during the study period. Receiving a diagnosis of HCV was associated with a decrease of 0.35 injections per month (p=0.046) but there was no change in injecting equipment borrowing (p=0.750). CONCLUSIONS: A small reduction in injecting frequency was observed in PWID who received a diagnosis of HCV. This finding should be investigated further in larger studies examining a wider range of injecting risk behaviours.
Authors: T Spelman; M D Morris; G Zang; T Rice; K Page; L Maher; A Lloyd; J Grebely; G J Dore; A Y Kim; N H Shoukry; M Hellard; J Bruneau Journal: J Epidemiol Community Health Date: 2015-03-26 Impact factor: 3.710
Authors: Jason Grebely; Geert Robaeys; Philip Bruggmann; Alessio Aghemo; Markus Backmund; Julie Bruneau; Jude Byrne; Olav Dalgard; Jordan J Feld; Margaret Hellard; Matthew Hickman; Achim Kautz; Alain Litwin; Andrew R Lloyd; Stefan Mauss; Maria Prins; Tracy Swan; Martin Schaefer; Lynn E Taylor; Gregory J Dore Journal: Int J Drug Policy Date: 2015-07-17
Authors: Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore Journal: Int J Drug Policy Date: 2017-07-03
Authors: Natasha K Martin; Peter Vickerman; Iain F Brew; Joan Williamson; Alec Miners; William L Irving; Sushma Saksena; Sharon J Hutchinson; Sema Mandal; Eamonn O'Moore; Matthew Hickman Journal: Hepatology Date: 2016-03-22 Impact factor: 17.425
Authors: Jesse L Goldshear; Kelsey A Simpson; Alex H Kral; Lynn D Wenger; Ricky N Bluthenthal Journal: Subst Use Misuse Date: 2021-03-26 Impact factor: 2.362
Authors: Nick Scott; Elise R Carrotte; Peter Higgs; Mark A Stoové; Campbell K Aitken; Paul M Dietze Journal: PLoS One Date: 2017-05-31 Impact factor: 3.240